

# Savings in Sepsis

The Implementation and Impact of the Q-linea ASTar System within Mersey and West Lancashire NHS Teaching Hospitals Trust

## Background

Sepsis is a life-threatening disease associated with prolonged hospital stays.

Approximately 36-40% of sepsis cases in the UK are caused by Gram-negative bacteria [1], with 16,868 cases in the financial year of 2023-2024 [2].

Automated RAST methods can reduce laboratory turnaround times, which may improve patient pathways.

STANDARD OF CARE:  
VITEK2  
MIC STRIPS  
MBD



THE Q-LINEA  
ASTAR SYSTEM:  
BC G- KIT

## Aims

1

Reflect on validation data and how performance of the ASTar compared to the previous SoC.

2

Assess differences in turnaround times between the ASTar and the previous SoC.

3

Perform a cost-benefit analysis to ascertain the potential cost savings the NHS could achieve due to the impact of reduced turnaround times on patient pathways.

## Results

>95%

Mean accuracy, sensitivity and specificity of validation data.

1.73

Reduction in mean turnaround time in days.

$5.51 \times 10^{-7}$

P-value of reduction in turnaround time (hours).

~£2mil

Mean estimated annual cost saving per trust.

## Limitations

MICROBIOLOGY RESPONSE

WARD RESPONSE

PHARMACY FULFILMENT

## Potential Improvements to Patient Pathways due to Reduced Turnaround Time

